Skin Rash
Clinical Presentation
FDA grants fast track designation to ATR-04 for cancer therapy-induced skin rash
The FDA has granted fast track designation to topically applied ATR-04 for the treatment of moderate to severe epidermal growth factor receptor inhibitor-associated dermal toxicity, Azitra announced in a press release.
FDA clears development of drug to treat cancer therapy-induced skin rash
The FDA has cleared an investigational new drug application for a first-in-human phase 1/2 study of ATR-04 for moderate to severe dermal toxicity from epidermal growth factor receptor inhibitors, Azitra Inc. announced in a press release.
National Rosacea Society to issue seals of acceptance on rosacea-friendly products
The National Rosacea Society is launching a Seal of Acceptance program that will assist individuals suffering from rosacea in finding rosacea-friendly products, the society announced in a press release.
8-year-old girl presents to ED with painful rash and fever
An 8-year-old female presented to the ED with a painful eruption for 6 days’ duration. She had a history of moderate eczema that was flaring for the past few weeks and was being managed with topical steroids.